Puget Sound Drug Corporation dba Key Pharmacy and Compounding Center – FDA 483, Jun 13, 2019

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified four key deficiencies related to the firm's quality system and manufacturing operations.

Observation 1 notes the firm's failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This indicates a potential risk to product sterility and patient safety.

Observation 2 states that the firm did not adequately validate the sterilization process for production equipment. This is a critical deficiency as it directly impacts the sterility assurance of manufactured products.

Observation 3 highlights the firm's failure to conduct routine calibration of critical manufacturing equipment. Uncalibrated equipment can lead to inaccurate measurements and non-conforming products.

Observation 4 indicates that the firm did not adequately investigate discrepancies and failures found in batch production records. This suggests a lack of robust root cause analysis and corrective action processes, potentially allowing recurring issues to go unaddressed.

Collectively, these observations point to significant deficiencies in the firm's quality control, equipment management, and deviation handling systems, which are fundamental requirements for current Good Manufacturing Practices (cGMP). The business implications include potential regulatory action, product recalls, and damage to reputation if these issues are not promptly and effectively remediated.